Madrigal Pharmaceuticals extended its metabolic dysfunction–associated steatohepatitis (MASH) expansion with additional licensing activity linked to Arrowhead Pharmaceuticals’ siRNA assets, continuing a run of deals aimed at complementing its FDA-approved therapy Rezdiffra. The company’s latest agreements target genetically defined drivers of MASH and reinforce Madrigal’s approach of pairing broad baseline benefits with precision mechanism add-ons. On the performance side, Madrigal’s first-quarter Rezdiffra results landed above analyst expectations, with reported sales of $311M—significantly informing near-term confidence in the commercial platform. Combined with the deal activity, the updates signal that MASH remains a capital-attracting therapeutic area with multiple overlapping competitive strategies. Together, the licensing news and earnings beat add weight to Madrigal’s positioning as the category consolidator, while keeping pressure on other liver fibrosis and cardiometabolic competitors to defend differentiation.